Receptor subtypes mediating the inotropic effects and Ca2+ signaling induced by endothelin-1 through crosstalk with norepinephrine in canine ventricular myocardium

Journal of Pharmacological Sciences

Volumn 97, Issue 3, 2005, Pages 417-428

  Chu, Li ^a,b   Zhang, Jian Xin ^a,c   Norota, Ikuo ^a   Endoh, Masao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Hebei Institute of Medical Science   (China)

Author keywords

Canine ventricular myocardium; Endothelin receptor subtype; Endothelin 1; Inotropic effect; Norepinephrine

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FR 319317; GENISTEIN; INDO 1; ISOPRENALINE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NORADRENALIN; PENTOBARBITAL; PRAZOSIN; PROTEIN KINASE INHIBITOR; TAK 044; TIMOLOL; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SELECTIVITY; FEMALE; FLUORESCENCE; HEART MUSCLE; INOTROPISM; MALE; MUSCLE FIBER CONTRACTION; NONHUMAN;

EID: 17144422157     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FP0040959     Document Type: Article

References (40)

1. Yanagisawa M, Kusumoto H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
2. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation. 1991;84:1457-1468.
3. Haynes WG, Davenport AP, Webb DJ. Endothelin: progress in pharmacology and physiology. Trends Pharmacol Sci. 1993;14: 225-228.
4. Serneri GG, Cecioni I, Vanni S, Paniccia R, Bandinelli B, Vetere A, et al. Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. Circ Res. 2000;86:377-385.
5. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-876.
6. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325-415.
7. Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol. 1996;72:261-290.
8. 2+ transients and contractility in rabbit ventricular. Life Sci. 1998;62:1485-1489.
9. Takanashi M, Endoh M. Characterization of the positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol. 1991;261:H611-H619.
10. Kasai H, Takanashi M, Takasaki C, Endoh M. Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. Am J Physiol. 1994;266:H2220-H2228.
11. 2+ signaling in contractile regulation induced by crosstalk between endothelin-1 and norepinephrine in dog ventricular myocardium. Circ Res. 2003;92: 1024-1032.
12. Zhu Y, Yang TH, Endoh M. Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle. Am J Physiol. 1997;273:H119-H127.
13. 2+ sensitivity in rabbit ventricular myocytes. Eur J Pharmacol. 2001;424:91-96.
14. 2+ current in dog ventricular myocytes. J Cardiovasc Pharmacol. 2000;36:344-350.
15. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440-3450.
16. Chu L, Endoh M. Biphasic inotropic response to endothelin-1 in the presence of various concentrations of norepinephrine in dog ventricular myocardium. J Cardiovasc Pharmacol. 2000;36 Suppl 2:S9-S14.
17. 2+ signaling in aequorin-loaded canine right ventricular myocardium [abstract]. Jpn J Pharmacol. 2001;85 Suppl I:81P.
18. Chu L, Endoh M. Genistein enhances the positive inotropic effect of norepinephrine, but inhibits the positive and negative inotropic effect of endothelin-1 induced by cross talk with norepinephrine in canine ventricular myocardium. Circulation. 2001;89 Suppl 2:S21.
19. 2+ induced by crosstalk of endothelin-1 and norepinephrine in canine myocardium [abstract]. Jpn J Pharmacol. 2002;88 Suppl I:64P.
20. Takanashi M, Endoh M. Concentration- and time-dependence of phosphoinositide hydrolysis induced by endothelin in relation to the positive inotropic effect in rabbit ventricular myocardium. J Pharmacol Exp Ther. 1992;262:1189-1194.
21. Talukder MA, Norota I, Sakurai K, Endoh M. Inotropic response of rabbit ventricular myocytes to endothelin-1: difference from isolated papillary muscles. Am J Physiol. 2001;281:H596-H605.
22. Sekine T, Kusano H, Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Developmental conversion of inotropism by endothelin I and angiotensin II from positive to negative in mice. Eur J Pharmacol. 1999;374:411-415.
23. Sakurai K, Norota I, Tanaka H, Kubota I, Tomoike H, Endoh M. Negative inotropic effects of angiotensin II, endothelin-1 and phenylephrine in indo-1 loaded adult mouse ventricular myocytes. Life Sci. 2002;70:1173-1184.
24. 2+ current in rabbit ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1999;360: 654-664.
25. Hartzell HC. Regulation of cardiac ion channels by catecholamines, acetylcholine and second messenger systems. Prog Biophys Mol Biol. 1988;52:165-247.
26. 2+ current. Pflugers Arch. 1986;407:182-189.
27. Isenberg G, Belardinelli L. Ionic basis for the antagonism between adenosine and isoproterenol on isolated mammalian ventricular myocytes. Circ Res. 1984;55:309-325.
28. 2+ current enhanced by isoprenaline in rat atrial myocytes. J Cardiovasc Pharmacol. 1997;29:136-143.
29. 2+ current in guinea-pig ventricular myocytes. J Physiol (Lond). 1997;503: 55-65.
30. Chu L, Norota I, Yomogida S, Ishii K, Endoh M. Differential inotropic effects of endothelin-1, angiotensin II, and phenylephrine induced by crosstalk with cAMP-mediated signaling process in dog ventricular myocardium. J Pharmacol Sci. 2004;96:199-207.
31. Ono K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, Ozaki Y, et al. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature. 1994;370: 301-304.
32. 2+ currents enhanced by isoproterenol in guinea-pig ventricular myocytes. Pflugers Arch. 1996;431:533-539.
33. Chu L, Norota I, Ishii K, Endoh M. Inhibitory action of the phosphatase inhibitor cantharidin on the endothelin-1-induced and the carbachol-induced negative inotropic effect in the canine ventricular myocardium. J Cardiovasc Pharmacol. 2003;41 Suppl 1: S89-S92.
34. 2+ current by endothelin in guinea pig atrial cells. Eur J Pharmacol. 1995;285:217-220.
35. B receptors in regulation of cardiac contractile function in mice. Am J Physiol. 2003;285:H112-H118.
36. Yomogida S, Maruya J, Norota I, Ishii K, Endoh M. Differential inhibition by TAK-044 of the inotropic effects of endothelin-1 and endothelin-3. Eur J Pharmacol. 2004;492:217-224.
37. B receptors in rats. Biochem Biophys Res Commun. 1994;199: 1461-1465.
38. Minami M, Yasuda H, Yamazaki N, Kojima S, Nishijima H, Matsumura N, et al. Plasma norepinephrine concentration and plasma dopamine-β-hydroxylase activity in patients with congestive heart failure. Circulation. 1983;67:1324-1329.
39. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation. 1994;89:1580-1586.
40. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85: 1374-1379.